RxDoctor Payments Data

Lowell Kabnick

Morristown, NJNPI 1477533925

Payments from drug & device makers

What this record shows

This record is dominated by royalties or licence payments: $821,916 of the $1,364,338 with a category attached, or 60.2%. Angiodynamics, Inc. accounts for 89.3% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $507,359 and has fallen 73.7% since, to $133,591 in 2025.

$1,364,338in general payments, 2019–2025

Across 155 payments — averaging $8802.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$1.2M
  • Boston Scientific$124K
  • Bard Peripheral Vascular, Inc.$21K
  • Medtronic$436
  • Venclose Inc.$181
  • Johnson & Johnson$55
  • plus $27 from 1 others

What the payments were for

  • Royalty or licence$821,91660%
  • Consulting fees$429,40331%
  • Speaking & faculty fees$16,8501%
  • Travel & lodging$26,6722%
  • Food & beverage$8,8331%
  • Ownership interest$60,6654%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Angiodynamics, Inc.36$1,218,260
Boston Scientific40$123,937
Bard Peripheral Vascular, Inc.69$21,443
Medtronic4$436
Venclose Inc.1$181
Johnson & Johnson4$55
Organogenesis Inc.1$27

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Where these figures come from

Is this you, or does something look wrong? →